Billings Clinic is participating in a national trial to study the use of an advanced device to treat patients with atrial fibrillation who are at higher risk for stroke and we are enrolling participants now.
Called the CHAMPION-AF trial and initiated by Boston Scientific, it is a randomized head-to-head trial designed to evaluate the safety and efficacy of the next-generation WATCHMAN FLX Left Atrial Appendage Closure Device within a broad population of patients with non-valvular atrial fibrillation (AF), including those who are at low-to-moderate risk of bleeding from the use of blood thinners. The device will be compared to results from leading contemporary blood thinner medications for stroke risk reduction in this population and provide a procedural option for those who may not otherwise qualify for the WATCHMAN device.